PinnyPeptide

KPV vs LL-37

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

KPV

Healing & Recovery

Anti-inflammatory tripeptide derived from alpha-melanocyte stimulating hormone.

Peptide B

LL-37

Healing & Recovery

Human antimicrobial peptide with broad-spectrum pathogen defense and wound-healing activity.

Typical vial

5 mg

Typical dose

200-500 mcg

Half-life

~15-30 minutes (short half-life typical of small peptides)

FDA status

Not FDA approved for human use.

Typical vial

5 mg

Typical dose

50-100 mcg

Half-life

~15-30 minutes (rapidly degraded by proteases)

FDA status

Not FDA approved for human use.

KPV effects

  • Potent anti-inflammatory action via NF-kB inhibition
  • Reduces intestinal inflammation when taken orally
  • Exhibits antimicrobial activity against bacteria and fungi
  • Modulates pro-inflammatory cytokine release
  • Supports gut barrier integrity

LL-37 effects

  • Broad-spectrum antimicrobial activity against bacteria, fungi, and viruses
  • Disrupts biofilm formation
  • Promotes wound healing and angiogenesis
  • Modulates innate immune responses
  • Neutralizes bacterial endotoxins (LPS)

KPV side effects

  • Generally well tolerated at studied doses
  • Mild gastrointestinal discomfort at higher doses
  • Temporary skin flushing (rare)

LL-37 side effects

  • Injection site redness and irritation
  • Potential cytotoxicity at high concentrations
  • Possible mast cell activation
  • Localized skin reactions

KPV dosing ranges

Gut inflammation support

200-500 mcg · Once or twice daily (oral or SubQ) · 4-8 weeks

Systemic anti-inflammatory

200-500 mcg · Once daily (SubQ) · 4-6 weeks

LL-37 dosing ranges

Antimicrobial support

50-100 mcg · Once daily (SubQ) · 2-4 weeks

Wound healing support

50-100 mcg · Once daily near affected area · 2-4 weeks

Full KPV guide → Full LL-37 guide →

KPV vs LL-37 — common questions

What is the difference between KPV and LL-37?

KPV: Anti-inflammatory tripeptide derived from alpha-melanocyte stimulating hormone. Typical dose 200-500 mcg. LL-37: Human antimicrobial peptide with broad-spectrum pathogen defense and wound-healing activity. Typical dose 50-100 mcg. Both fall under the Healing & Recovery category.

Can you stack KPV and LL-37?

Stacking KPV with LL-37 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, KPV or LL-37?

KPV is typically dosed: Once or twice daily (oral or SubQ) for Gut inflammation support; Once daily (SubQ) for Systemic anti-inflammatory. LL-37 is typically dosed: Once daily (SubQ) for Antimicrobial support; Once daily near affected area for Wound healing support.

Are KPV and LL-37 FDA approved?

KPV: Not FDA approved for human use. LL-37: Not FDA approved for human use.

Related peptide comparisons

ara-290 vs kpvbpc-157 vs kpvkpv vs tb-500kpv vs tb-500-frag-17-23kpv vs thymosin-alpha-1bpc-157 vs ll-37

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free